Welcome to our dedicated page for Statera Biopharma news (Ticker: STAB), a resource for investors and traders seeking the latest updates and insights on Statera Biopharma stock.
Statera Biopharma Inc (STAB) maintains this comprehensive news hub for stakeholders tracking advancements in immune health therapeutics. Our repository consolidates official announcements, clinical development updates, and strategic partnership disclosures related to the company's innovative drug repurposing strategies.
Investors and researchers will find timely updates on STAB's therapeutic pipeline, including progress in leveraging natural analogs for immune modulation. All content undergoes verification to ensure accurate representation of regulatory milestones and scientific developments.
This resource features essential updates across key operational areas: clinical trial phases, intellectual property developments, collaborative research initiatives, and financial reporting. Each announcement is contextualized within the company's mission to restore homeostasis through pleiotropic drug effects.
For consistent access to verified information about STAB's biopharmaceutical innovations, consider bookmarking this page or setting up news alerts through your preferred financial platform. Always cross-reference materials with official SEC filings and peer-reviewed publications for complete due diligence.
Tivic Health Systems (NASDAQ: TIVC) has acquired worldwide exclusive license rights from Statera Biopharma for Entolimod™, a late-stage TLR5 agonist targeting acute radiation syndrome (ARS). The agreement includes an exclusive option for five additional indications for Entolimod and its derivative, Entalasta™.
This strategic move transforms Tivic from a single-product, direct-to-consumer company into a diversified therapeutics company. Entolimod has received FDA Fast Track and Orphan Drug designation for ARS treatment and has undergone over forty animal and human trials with $140 million in prior investment.
The global ARS market is valued at $5.2 billion in 2024, with a projected 5% annual growth rate through 2031. The acquisition positions Tivic to address immune and autonomic dysregulation through both neural and molecular pathways, with potential FDA approval within 24 months.
Statera Biopharma (OTCPK:STAB) has signed a non-binding letter of intent with Worksite Labs, Inc. to explore a merger. This strategic move aims to enhance shareholder value and operational performance by aligning Statera's goals with Worksite Labs' diagnostic services. Worksite Labs generated over $50 million in revenues in 2022 and aims to leverage capital markets for accelerated growth. Completion of the merger is contingent upon due diligence, definitive agreements, and necessary approvals. Both companies are optimistic about the benefits this combination could bring to their operations and market positioning.
Statera Biopharma (NASDAQ:STAB) has completed its application to uplist from OTC Pink Sheets to the OTCQB Venture Marketplace. This marks a crucial step in its efforts to regain a NASDAQ listing. The company anticipates that this transition will lead to improved investor benefits, including enhanced reporting standards and increased visibility among analysts and institutional investors. The addition of CG Capital as an advisor aims to further increase trading liquidity and broaden STAB's shareholder base. Statera develops immune therapies targeting autoimmune diseases, cancers, and emerging viruses based on a proprietary platform.
Statera Biopharma, a biopharmaceutical company (NASDAQ:STAB), received a favorable decision from the Nasdaq Hearings Panel, allowing them to maintain their listing on Nasdaq, contingent upon meeting specific interim milestones. This decision was made on October 26, 2022, requiring compliance with the $1.00 bid price and $2.5 million stockholders' equity standards by January 31, 2023. The company specializes in developing innovative immune therapies targeting autoimmune diseases and cancers, positioned to enhance patient immune responses using toll-like receptor (TLR) agonists.
Statera Biopharma (NASDAQ:STAB) filed its Q1 Form 10-Q for the period ending March 31, 2022, with the SEC, while also working on the Q2 report. The company secured an agreement with Silverback Capital to acquire $400,000 of a $15 million promissory note, converting it into an amended convertible note due May 1, 2024. This move aims to enhance Statera's financial standing. CEO Michael Handley expressed confidence in complying with NASDAQ regulations and hopes for further note conversions to improve the balance sheet.
Statera Biopharma (NASDAQ:STAB) has signed a MOU with Holobeam Technologies to acquire a 25% stake, granting access to Holobeam's innovative diagnostic technology. This partnership aims to enhance early cancer detection and treatment efficacy through Holobeam's patented Holographic Energy Teleportation (HET) technology, which promises to identify cancers earlier and target therapies more precisely. The exclusivity period for finalizing the agreement is set for 60 days. The alliance could significantly improve the therapeutic outcomes for cancer patients by enabling targeted drug delivery and early intervention.
Statera Biopharma (NASDAQ:STAB) announced the completion of its fiscal 2021 audit and filed its Annual Report on Form 10-K with the SEC. The company is now focused on filing Forms 10-Q for the first three quarters of 2022. At a Nasdaq hearing, Statera presented its compliance plan and requested an extension for continued listing. However, there is no assurance the request will be granted. Statera develops innovative immunotherapies targeting autoimmune diseases and cancers, leveraging a robust platform of TLR agonists.
Statera Biopharma (NASDAQ:STAB) announced on September 1, 2022, that it may face delisting from Nasdaq due to non-compliance with filing requirements. The company has not filed its Form 10-K for 2021 or the Forms 10-Q for the first two quarters of 2022. A hearing has been requested, scheduled for October 6, 2022, to seek an extension and demonstrate compliance. Statera develops immunotherapies for autoimmune diseases and cancers, with several clinical programs underway.
Statera Biopharma (NASDAQ: STAB) announced it received another notice of non-compliance from Nasdaq due to its failure to timely file the Form 10-Q for Q2 2022 with the SEC. This follows previous notices regarding the company's Forms 10-K and 10-Q for earlier periods. Statera intends to submit a plan to regain compliance within the allotted timeframe, which allows for a maximum of 180 days from the initial delinquent filing due date of October 17, 2022. However, the company cannot assure that it will meet Nasdaq’s compliance criteria.
Statera Biopharma (NASDAQ: STAB) has appointed BF Borgers CPA PC as its independent accountant to audit its financial statements for the year ended December 31, 2021. This move aims to enhance transparency and reliability in Statera’s financial reporting. The company specializes in developing immune therapies to address autoimmune diseases, cancers, and emerging viruses, leveraging its proprietary platform. Statera's clinical programs include treatments for Crohn’s disease, hematology, pancreatic cancer, and COVID-19.
FAQ
What is the current stock price of Statera Biopharma (STAB)?
What is the market cap of Statera Biopharma (STAB)?
